Abbott Laboratories $ABT Shares Acquired by Cibc World Market Inc.

Cibc World Market Inc. lifted its holdings in shares of Abbott Laboratories (NYSE:ABT) by 8.0% during the 4th quarter, HoldingsChannel.com reports. The fund owned 393,915 shares of the healthcare product maker’s stock after buying an additional 29,139 shares during the period. Cibc World Market Inc.’s holdings in Abbott Laboratories were worth $49,354,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in ABT. Brighton Jones LLC increased its stake in Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock worth $5,850,000 after buying an additional 4,755 shares during the period. Sivia Capital Partners LLC increased its stake in Abbott Laboratories by 3.5% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock worth $648,000 after buying an additional 162 shares during the period. United Bank increased its stake in Abbott Laboratories by 7.4% during the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock worth $3,945,000 after buying an additional 2,001 shares during the period. Main Street Financial Solutions LLC increased its stake in Abbott Laboratories by 13.6% during the 2nd quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker’s stock worth $1,618,000 after buying an additional 1,428 shares during the period. Finally, Canada Pension Plan Investment Board increased its stake in Abbott Laboratories by 25.6% during the 2nd quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker’s stock worth $195,267,000 after buying an additional 292,547 shares during the period. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Price Performance

ABT opened at $90.71 on Friday. The company has a 50-day moving average of $93.07 and a 200-day moving average of $109.44. The company has a market capitalization of $157.99 billion, a P/E ratio of 25.41, a PEG ratio of 1.45 and a beta of 0.63. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $139.06. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.01. The company had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The company’s revenue was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities analysts expect that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on ABT shares. Daiwa Securities Group downgraded shares of Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price target on the stock. in a research note on Wednesday, April 22nd. JPMorgan Chase & Co. dropped their price target on shares of Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. Barclays dropped their price target on shares of Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a research note on Monday, April 20th. BTIG Research reissued a “buy” rating and issued a $131.00 target price on shares of Abbott Laboratories in a research report on Monday, April 27th. Finally, Benchmark dropped their target price on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $119.09.

Insider Transactions at Abbott Laboratories

In related news, Director Daniel J. Starks purchased 10,000 shares of the company’s stock in a transaction dated Monday, April 27th. The shares were acquired at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the transaction, the director owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Philip P. Boudreau purchased 2,200 shares of the business’s stock in a transaction that occurred on Thursday, April 23rd. The stock was bought at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the acquisition, the chief financial officer owned 2,200 shares in the company, valued at approximately $201,300. The trade was a ? increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 0.46% of the stock is owned by corporate insiders.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.